Johannesburg, South Africa
Johannesburg, South Africa

Time filter

Source Type

News Article | May 12, 2017
Site: www.prweb.com

Pyxant Labs has added 12 full-time staff at its Colorado Springs site and 13 additional people at other US locations. These recent personnel additions follow facility improvements, laboratory equipment additions, and IT systems enhancements during 2016. These people bring our total employment to 53 people, further building our best-in-the-industry team. Our medication management clinical toxicology services now provide 24-hour turnaround time for most Colorado clinics and hospitals. We assess 85 drugs and metabolites, such as opioids, antidepressants, and drugs of abuse, among others. We will offer less-than-48-hour turnaround for perinatal umbilical cord toxicology testing starting in July 2017. This clinical toxicology assay supports physician diagnoses of opioid withdrawal and other drug dependencies in newborn babies. Treatment of drug dependence in newborns is more effective and safer when a doctor can confirm the particular source of drug dependency, fast following birth. This service includes same-day local courier pickup and delivery of specimens from Colorado hospitals. Our turnaround time is the fastest in the industry; doctors commonly wait three weeks to receive this test result. “The experience Pyxant Labs has gained in the past 17 years serving the highly stringent pharmaceutical industry has been instrumental in building a best-in-class Clinical Laboratory Services division. From the onset, Pyxant Labs CLS has one the most qualified and efficient LC/MS/MS method development teams in the entire industry. Furthermore, the extensive experience Pyxant Labs has gained working in the highly regulated drug development environment, which includes five FDA and numerous pharmaceutical company inspections, makes Pyxant Labs CLS one of the laboratories that observes the most rigorous regulatory operations and the laboratory of choice to send your specialty samples to. The clinical industry, especially the medication management sector, needs a high quality laboratory like Pyxant Labs,” said Jean Pineault, President and COO. “Our business requires people with extensive scientific education, specialized training, and experience in chemistry, biology, toxicology, and clinical healthcare. Attracting the right people is of course crucial to fast growth, especially considering our science, quality, and regulatory performance paradigms. I particularly appreciate the support of the Colorado Springs Chamber and EDC, who supported attracting key people with unique skills from the East Coast to relocate to Colorado Springs and join Pyxant Labs,” said Maurice Gaubatz, Founder and CEO. About Pyxant Labs – Pyxant Labs Inc. is a privately held bioanalytical laboratory, operating two business units: Pyxant Labs Contract Research Organization (CRO) provides bioanalytical support for FDA-regulated pharmaceutical development trials. Studies produce blood and tissue samples, which we assay in our analytical chemistry laboratory to determine how much of a new drug is in a subject at a particular point in time. Such evaluations support safety and efficacy studies of new pharmaceuticals, an essential requirement for FDA approval. Pyxant Labs Clinical Laboratory Services (CLS) is a fast-growing clinical toxicology business unit serving medical providers, other laboratories, and hospitals. We daily receive and assay urine, oral fluid, and tissue specimens for more than 85 drugs, including opioids, psychiatric drugs, cardiac meds, and street drugs. Our fast assay results provide insight for medical practitioners to improve patient outcomes through better management of medications. For more information, contact Kathy Bouard at 719-593-1165 or kbouard(at)pyxant(dot)com - http://www.pyxant.com


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Clinical Laboratory Market: by-Country Market Analysis (U.S., China, Japan, Germany, France, Spain, Italy, Brazil, EMEA and others)" report to their offering. What's the Size of the Clinical Laboratory Market in Several Country Markets? Global Laboratory Market: by-Country Market Analysis (U.S., China, Japan, Germany, France, Spain, Italy, Brazil, EMEA and others) provides an overview of the clinical laboratory industry and the trends driving growth. Market data presented include the following: Internationally, the clinical laboratory market is growing. Clinical Laboratory Services Market presents information as a global focused market report. Key regions discussed include Northern America; Europe, Middle East, and Africa (EMEA); Asia Pacific; and Latin America. Datasets provided include the following: - Estimated U.S. Laboratory Service Revenues and Market Share of Leading Clinical Laboratory Providers, 2016 - Estimated U.S. Laboratory Service Revenues for Leading Clinical Laboratory Providers, 2010 vs. 2016 Trends and Issues discussed in this report are inclusive of population statistics, disease statistics, new issues, regulatory environment, laboratory regulation, reimbursement, payer types, and developments in personalized medicine. The clinical laboratory market is highly competitive in terms of prices, locations, and services offered. Larger laboratories have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. The report profiles companies that are the leaders in the industry, including: 3: Issues And Trends In The Clinical Laboratory Industry For more information about this report visit http://www.researchandmarkets.com/research/f262tx/global_clinical


What's the Size of the Clinical Laboratory Market in Several Country Markets? Global Laboratory Market: by-Country Market Analysis (U.S., China, Japan, Germany, France, Spain, Italy, Brazil, EMEA and others) provides an overview of the clinical laboratory industry and the trends driving growth. Market data presented include the following: Internationally, the clinical laboratory market is growing. Clinical Laboratory Services Market presents information as a global focused market report. Key regions discussed include Northern America; Europe, Middle East, and Africa (EMEA); Asia Pacific; and Latin America. Datasets provided include the following: - Estimated U.S. Laboratory Service Revenues and Market Share of Leading Clinical Laboratory Providers, 2016 - Estimated U.S. Laboratory Service Revenues for Leading Clinical Laboratory Providers, 2010 vs. 2016 Trends and Issues discussed in this report are inclusive of population statistics,  disease statistics, new issues, regulatory environment, laboratory regulation, reimbursement, payer types, and developments in personalized medicine. The clinical laboratory market is highly competitive in terms of prices, locations, and services offered. Larger laboratories have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. The report profiles companies that are the leaders in the industry, including: 3: Issues And Trends In The Clinical Laboratory Industry - Certificate of Compliance and Certificate of Accreditation - ALERE, Inc - Bio-Reference Laboratories - OPKO - Davita Healthcare Partners, Inc. - Genomic Health, Inc. - Genomic Health, Inc. - Laboratory Corporation of America - Myriad Genetics, Inc. - Neogenomics, Inc. - Quest Diagnostics, Inc. - Siemens Healthineers - Sonic Healthcare Limited - Spectra Laboratories: A Fresenius Company - Synlab International Gmbh For more information about this report visit http://www.researchandmarkets.com/research/m9hsjn/global_clinical Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-clinical-laboratory-market-analysis-2010-2021-market-leaders-are-quest-diagnostics-bio-reference-laboratories-opko-genomic-health-laboratory-corporation-of-america--myriad-genetics-300462442.html


Ocean View, Delaware, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Clinical Laboratory Services Market size was USD 196.9 billion in 2015, with 6.4% CAGR estimation from 2016 to 2024; as per a new research report by Global Market Insights, Inc. Growing importance of early diagnosis of chronic diseases related to oncology, gynaecology and endocrinology should drive global clinical laboratory services market size. Moreover, introduction of technologically advanced products rendering accurate and rapid results should spur industry growth over the forecast years. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/807 Increased adoption of laboratory automations and robot assisted laboratory techniques such as TECAN liquid handling robotics will spur growth.  For instance, over 30% of laboratories in North America, Europe and Japan have implemented a significant degree of laboratory automation. Additionally, growing use of healthcare IT systems have enabled implementation of technologically advanced processes. Introduction of innovative solutions that allows implementation of informatics and data management systems to perform rapid and seamless operations with accurate clinical results with higher efficiency will accelerate industry growth. Chemistry segment held the largest clinical laboratory services market share with revenue slated to exceed USD 152 billion by 2024. Increasing prevalence of cardiovascular, diabetes, liver & kidney disorders coupled with growing awareness for early diagnosis will spur industry growth. U.S. held the largest share owing to high patient awareness and presence of large test volumes. APAC and LATAM will provide lucrative growth opportunities to industry players with introduction of regulatory standards to encourage the use of clinical laboratory services in these regions. Accounting for over one third of the global population, India and China are eyed upon as potential business hubs for clinical laboratory testing service providers. The key industry players include Quest Diagnostics, Sonic Healthcare, LabCorp, Genoptix Medical Laboratory, Healthscope, Labco, Charles River Laboratories and Bio-Reference Laboratories, Abbott Laboratories. The key strategies of mergers and acquisitions and strategic collaborations will enable industry players to strengthen their regional presence. Browse key industry insights spread across 110 pages with 33 market data tables & 10 figures & charts from the report, “Clinical Laboratory Services Market Size By Test (Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology, Other Esoteric Test), By Service Provider (Hospitals, Stand-Alone Laboratories, Clinics), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Japan, China, Brazil, Mexico, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024” in detail along with the table of contents: Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/807 Clinical laboratory services market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD billion from 2012 to 2024 , for the following segments: The above information is provided on a regional and country basis for the following: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


News Article | November 16, 2016
Site: www.newsmaker.com.au

Clinical Laboratory Services Market size is estimated to reach USD 342.3 billion by 2024; as per a new research report by Global Market Insights, Inc. Growing importance of early diagnosis of chronic diseases related to oncology, gynaecology and endocrinology should drive global clinical laboratory services market size. Moreover, introduction of technologically advanced products rendering accurate and rapid results should spur industry growth over the forecast years. Increased adoption of laboratory automations and robot assisted laboratory techniques such as TECAN liquid handling robotics will spur growth.  For instance, over 30% of laboratories in North America, Europe and Japan have implemented a significant degree of laboratory automation. Additionally, growing use of healthcare IT systems have enabled implementation of technologically advanced processes. Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/807 Introduction of innovative solutions that allows implementation of informatics and data management systems to perform rapid and seamless operations with accurate clinical results with higher efficiency will accelerate industry growth. Chemistry segment held the largest clinical laboratory services market share with revenue slated to exceed USD 152 billion by 2024. Increasing prevalence of cardiovascular, diabetes, liver & kidney disorders coupled with growing awareness for early diagnosis will spur industry growth. U.S. held the largest share owing to high patient awareness and presence of large test volumes. APAC and LATAM will provide lucrative growth opportunities to industry players with introduction of regulatory standards to encourage the use of clinical laboratory services in these regions. Accounting for over one third of the global population, India and China are eyed upon as potential business hubs for clinical laboratory testing service providers. The key industry players include Quest Diagnostics, Sonic Healthcare, LabCorp, Genoptix Medical Laboratory, Healthscope, Labco, Charles River Laboratories and Bio-Reference Laboratories, Abbott Laboratories. The key strategies of mergers and acquisitions and strategic collaborations will enable industry players to strengthen their regional presence. Browse key industry insights spread across 110 pages with 33 market data tables & 10 figures & charts from the report, “Clinical Laboratory Services Market Size By Test (Human & Tumor Genetics, Clinical Chemistry, Medical Microbiology & Cytology, Other Esoteric Test), By Service Provider (Hospitals, Stand-Alone Laboratories, Clinics), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Japan, China, Brazil, Mexico, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024” in detail along with the table of contents: Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.


Demers A.-M.,University of Cape Town | Venter A.,University of Cape Town | Friedrich S.O.,University of Cape Town | Rojas-Ponce G.,National Institute of Medical Research | And 12 more authors.
Journal of Clinical Microbiology | Year: 2016

Pyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available. PZA drug susceptibility testing (DST) was performed directly on sputum samples from 327 patients and compared with the indirect method by using the Bactec MGIT 960 system in the context of patient screening for participation in a drug trial. Compared to standard indirect PZA DST, direct DST was successful in only 59% of cases, but results obtained were highly accurate and available faster. Agreement between the direct and indirect methods varied from 90 to 100% in each laboratory. The median times for obtaining PZA results from the time when the specimen was collected ranged from 11 to 16 days for the direct test and 18 to 95 days for the indirect test across laboratories. The direct method is accurate and reproducible across laboratories. It can be expected to accelerate results in > 50% of cases, but it cannot replace indirect DST for PZA. Phenotypic methods remain the gold standard for DST in drug trials. If future studies can optimize the method to decrease the number of uninterpretable results, direct MGIT DST could be the new phenotypic DST standard for clinical trials, providing more rapid detection of resistance to new drugs in experimental regimens. Copyright © 2016 Demers et al.


PubMed | National Institute of Medical Research, University of Arkansas for Medical Sciences, KwaZulu Natal Research Institute for Tuberculosis and HIV, Global Alliance for TB Drug Development and 4 more.
Type: Journal Article | Journal: Journal of clinical microbiology | Year: 2016

Pyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available. PZA drug susceptibility testing (DST) was performed directly on sputum samples from 327 patients and compared with the indirect method by using the Bactec MGIT 960 system in the context of patient screening for participation in a drug trial. Compared to standard indirect PZA DST, direct DST was successful in only 59% of cases, but results obtained were highly accurate and available faster. Agreement between the direct and indirect methods varied from 90 to 100% in each laboratory. The median times for obtaining PZA results from the time when the specimen was collected ranged from 11 to 16 days for the direct test and 18 to 95 days for the indirect test across laboratories. The direct method is accurate and reproducible across laboratories. It can be expected to accelerate results in >50% of cases, but it cannot replace indirect DST for PZA. Phenotypic methods remain the gold standard for DST in drug trials. If future studies can optimize the method to decrease the number of uninterpretable results, direct MGIT DST could be the new phenotypic DST standard for clinical trials, providing more rapid detection of resistance to new drugs in experimental regimens.


Singhi A.K.,Madras Medical Mission | Vinoth B.,Madras Medical Mission | Kuruvilla S.,Clinical Laboratory Services | Sivakumar K.,Madras Medical Mission
Annals of Pediatric Cardiology | Year: 2015

Plastic bronchitis, a rare but serious clinical condition, commonly seen after Fontan surgeries in children, may be a manifestation of suboptimal adaptation to the cavopulmonary circulation with unfavorable hemodynamics. They are ominous with poor prognosis. Sometimes, infection or airway reactivity may provoke cast bronchitis as a two-step insult on a vulnerable vascular bed. In such instances, aggressive management leads to longer survival. This report of cast bronchitis discusses its current understanding.


Rahman H.,Clinical Laboratory Services | Razzak M.A.,Clinical Laboratory Services | Chanda B.C.,Clinical Laboratory Services | Bhaskar K.R.,Clinical Laboratory Services | Mondal D.,Center for Nutrition and Food Security
Journal of Health, Population and Nutrition | Year: 2014

Cutaneous leishmaniasis (CL), an uncommon disorder in South-East Asia, including Bangladesh, often presents as granulomatous plaque on the exposed areas, with a high index of suspicion required for diagnosis. Here we report the first imported case of CL caused by Leishmania tropica in a migrant Bangladeshi worker in the Kingdom of Saudi Arabia (KSA). The case, initially suspected as a case of cutaneous tuberculosis, arrived at specimens reception unit (SRU) of diagnostic labs of icddr,b being referred by the physician for ALS testing for tuberculosis. At his arrival in the SRU, one of the health personnel of the unit who used to work in KSA suspected him as a case of CL. The diagnosis was confirmed by smear microscopy which revealed plenty of amastigotes within macrophages. PCR was performed to confirm the species. He was treated with sodium stibogluconate at Shahid Suhrawardy Medical College Hospital, Dhaka. © International centre for diarrhoeal disease research, Bangladesh.


News Article | February 21, 2017
Site: www.prnewswire.com

NEW YORK, Feb. 20, 2017 /PRNewswire/ -- This Report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Segments: Hospital-Based Laboratories, Independent Laboratories, and Physician Office-Based Laboratories. The report provides separate...

Loading Clinical Laboratory Services collaborators
Loading Clinical Laboratory Services collaborators